

POSTERS

P 1 Cervical neoplasia

| | | | |
|-------|---|----------------------|---------|
| P 1-1 | - Prognostic factors affecting survival in cervical cancer patients with recurrent parenchymal lung lesions without other organ involvement | B. Duk-Soo | Korea |
| P 1-2 | - The expression of S100A14 into cytosol is associated with cervical cancer growth. | J.H. Kim | Korea |
| P 1-3 | - Prognostic relevance of multiple HPV genotypes in cervical carcinoma | G. Lillsunde Larsson | Sweden |
| P 1-4 | - Application of topical imiquimod for treatment cervical intraepithelial neoplasia in young women: a preliminary result of a pilot study | J.H. Nam | Korea |
| P 1-5 | - Thin HSIL of the cervix: detecting a variant of high-grade squamous intraepithelial lesions with a p16INK4a - Antibody | O. Reich | Austria |
| P 1-6 | - Cervical cancer survivors and health care use: a population-based register study | M. Skorstengaard | Denmark |
| P 1-7 | - Estimating the management cost of cervical intraepithelial neoplasia in the UK | M. Uhart | France |
| P 1-8 | - Dynamin 2 inhibitors as novel therapeutic agents in cervical cancer cells | L. Jeong-Won | Korea |
| P 1-9 | - Expression of vascular endothelial growth factor-C and podoplanin in squamous intraepithelial lesion | N. Speck | Brazil |

P 2 Colposcopy and management

| | | | |
|-------|--|-----------------|--------|
| P 2-1 | - Counterfactuals of disease discovery within the Frida study | E. Barrios | Mexico |
| P 2-2 | - Sensitivity and specificity of cytology and colposcopy compared to final histology after LLETZ | A. Papanikolaou | Greece |

P 3 Conventional therapies

| | | | |
|-------|---|---------------|----------------|
| P 3-1 | - Fisher cone biopsy in the management of cervical cancer precursors | A. Dörr | Czech Republic |
| P 3-2 | - Obstetric outcome after conization or LLETZ: a retrospective study in the university hospital of Leuven | H. Verschuere | Belgium |

P 4 Cytology

| | | | |
|-------|---|--------------|---------|
| P 4-1 | - Cancer screening of cervical pregnancy in maternity center health Nabil Choucair and hospital institute social in Dakar (Senegal): about 67 cases | O. Gassama | Senegal |
| P 4-2 | - Clinical significance of atypical glandular cells on cytology | H.J. Kim | Korea |
| P 4-3 | - Management of abnormal pap smear during pregnancy | A.C. Porn | Germany |
| P 4-4 | - Human papillomavirus (HPV) prevalence and correlation with abnormal cervical cytology findings in women from Croatia: a compounding effect of low-risk/high-risk HPV co-infection | Z. Profozic | Croatia |
| P 4-5 | - Cytological evaluation in penile samples with human papillomavirus | K. Shigehara | Japan |
| P 4-6 | - Results of conventional cytology pap smear versus liquid-based cytology associated with HPV DNA testing in women with uterine cervical ectopy | N. Speck | Brazil |
| P 4-7 | - A population-based study on cervical cancer risk by screening history | H.C.Chen | Taiwan |

P 5 Diagnostic procedures

| | | | |
|-------|--|---------------|-----------|
| P 5-1 | - Comparison of Anyplex II HPV HR and HC2 testing in a screening population | A. Luyten | Germany |
| P 5-2 | - Evaluation of Seegene Anyplex II HPV genotyping assays using cervical samples | S. Tabrizi | Australia |
| P 5-3 | - Evaluation of sample cellularity and nucleic acids stability using Copan Enat medium associated with FLOQSWABS: self-collected versus clinician-vaginal sampling | M. Martinelli | Italy |

P 6 Economics and modelling

- P 6-1 - Health outcome and budget impact analysis of a combined cervical screening strategy based on primary HPV screening and triage with dual stain cytology in Belgium K. Vandeweyer Belgium

P 7 Epidemiology and natural history

- P 7-1 - Prolonged oral contraceptives use and the risk of acquisition of human papillomavirus type 16/18 infections I. Adhikari Finland
- P 7-2 - Cervical morbidity in Alsace, France. Results from a regional organized cervical cancer screening program J.J. Baldauf France
- P 7-3 - Prevalence of HPV infection among adolescent girls in Moscow region, Russian federation J. Belaya Russia
- P 7-4 - HPV and breast cancer...is there a relationship? S. Delgado García Spain
- P 7-5 - Epidemiology of hospitalizations related to cervical cancer in Spain (2009-2013) R. Gil-Prieto Spain
- P 7-6 - HPV-related cancer in Norway: secular incidence trends and preventive potential of HPV vaccination B.T. Hansen Norway
- P 7-7 - Cervical cancer incidence and mortality in the Russian federation S. Kharit Russia
- P 7-8 - Cervical screening history and rare histological types of invasive cervical cancer: a population-based nested case-control study in Sweden J. Lei Sweden
- P 7-9 - Seroprevalence of 19 human papillomavirus (HPV) types in a nationwide representative cross-sectional survey in Germany in the pre-vaccine era A. Loenenbach Germany
- P 7-10 - HPV prevalence and type-distribution in correlation with age and cervical cytologic abnormalities in Croatian female population T. Marijan Croatia
- P 7-11 - HR HPV virus presence in women-covered by national screening program for cervical carcinoma in Poland W. Olszewski Poland
- P 7-12 - Anal High Risk HVP: gender comparison for detection in Puerto Rican population A. Rosado Puerto Rico
- P 7-13 - German population-based analysis of risk factors for prevalent high risk HPV infections L. Wang Germany
- P 7-14 - Examining lung cancer tissue for human papillomavirus E. Panotopoulou Greece
- P 7-15 - Genital warts in Scandinavian women before and after implementation of HPV vaccination C. Munk Denmark
- P 7-16 - Trace elements and oxidative stress in cervical carcinogenesis R. Zappacosta Italy
- P 7-17 - HPV-related genital disease among men residing in Mexico E. Lazcano-Ponce Mexico

P 8 Genomics

- P 8-1 - The HPV 16 complete genome in two cervical progressive lesions from a 39-year-old woman differ from each other. F. Silveira Brazil
- P 8-2 - Analytical performance of HPV genotyping methods on cervical liquid based cytology samples M. Hansen Norway
- P 8-3 - MicroRNA-106b promotes cell migration by targeting DAB2 in cervical carcinoma L. Geng China

P 9 Health education

- P 9-1 - History and future of HPV college T. Fait Czech Republic
- P 9-2 - Population-based study about the knowledge of women on secondary prevention of cervical cancer M. Hernández Aragón Spain
- P 9-3 - Study about the anxiety generated by the result of screening techniques of cervical cancer L. Ruiz Campo Spain

Abstracts are available for download at: www.eurogin.com/2016

P 10 HPV and oropharynx / Head and neck cancer

| | | | |
|--------|---|--------------|------------|
| P 10-1 | - Comparative evaluation of three HPV genotyping assays on FFPE samples of head and neck cancer | J. Mossong | Luxembourg |
| P 10-2 | - Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including <i>Neisseria gonorrhoeae</i> , <i>Chlamydia trachomatis</i> , <i>Mycoplasma SPP</i> , and <i>Ureaplasma SPP</i> | K. Nakashima | Japan |
| P 10-3 | - PARP inhibition (OLAPARIB) in novel in-vitro models of oropharyngeal cancer | E. Pirotte | UK |

P 11 HPV prophylactic vaccines

| | | | |
|---------|--|------------------|----------|
| P 11-1 | - Effectiveness of HPV vaccine for the prevention of cervical abnormalities in Saitama City, Japan in 2015 | D. Hotta | Japan |
| P 11-2 | - The potential impact of papillomavirus vaccines in operable cervical tumours | M. Cunha | Portugal |
| P 11-3 | - HPV vaccine uptake rate in 9-21 year old adolescents during well-child visits from 2007 to 2013 in the U.S. | B. Lindsay | USA |
| P 11-4 | - 9-valent HPV vaccine development: innovative regulatory approach using a phase IIB/III design and an immunological bridging to establish efficacy | A. Fisher | USA |
| P 11-5 | - No increase in Guillain-Barre syndrome hospitalisations after HPV vaccine program implementation: an administrative database analysis in Québec, Canada | C. Sauvageau | Canada |
| P 11-6 | - Study of HPV vaccination in Greece during the last four years | A. Vatopoulou | Greece |
| P 11-7 | - The impact of the vaccination with bivalent HPV vaccine after electrosurgical conization in preventing of HPV infection in patients with high grade cervical intraepithelial neoplasia | N. Volodko | Ukraine |
| P 11-8 | - Early results of HPV-vaccination program with quadrivalent HPV vaccine depending on vaccine coverage in 3 districts of Moscow region, Russia | N. Zarochentseva | Russia |
| P 11-9 | - Public health impact and cost effectiveness of a universal vaccination programme with a nonavalent HPV vaccine in Germany | M. Uhart | France |
| P 11-10 | - Overcoming barriers to adolescent vaccination: vaccine champions' perspectives | J. Smith | USA |

P 12 HPV testing

| | | | |
|---------|--|------------------|----------|
| P 12-1 | - HPV infection among HIV-positive men: a three year revised experience of a diagnosis laboratory | A. Albuquerque | Portugal |
| P 12-2 | - Improving strategies and test algorithms for HPV diagnostics | F. Aliaga-Lozano | Spain |
| P 12-3 | - XPERT® HPV assay evaluation for HPV testing on formalin fixed paraffin embedded oropharyngeal squamous cell carcinomas | M. Benevolo | Italy |
| P 12-4 | - Audit of HPV subtypes in Northern Irish (NI) and Other Nationality (ON) patients with CIN111 biopsy | R. Clarke | UK |
| P 12-5 | - Evaluation of the management of HR-HPV+/pap test-women: results at 1-year recall | C. Di Cristofano | Italy |
| P 12-6 | - Impact of the new molecular Xpert HPV assay (CEPHEID) on laboratory organization and HPV management | I. Thibaut | France |
| P 12-7 | - Population-based HPV testing performance: potential false-negative HPV results in a cervical cancer surveillance population | M. Guo | USA |
| P 12-8 | - Distribution of high risk HPV genotypes in patients referred from medical offices in the Rhône-Alpes area (France) | M. Labadie | France |
| P 12-9 | - Performance of Cobas 4800 test to detect HRHPV in HSIL+ lesions | M.L.Mateos | Spain |
| P 12-10 | - Barriers to and facilitators of HPV self-testing among women post treatment of high grade CIN | M. Mints | Sweden |
| P 12-11 | - Comparison of the HPV DNA chip test, the RealTime PCR HPV test and the Hybrid capture II test in atypical squamous cells of undetermined significance population | J.S. Park | Korea |
| P 12-12 | - Evaluation of oncogenic human papillomavirus RNA and DNA test with liquid-based cytology in primary cervical cancer screening population | A. Sáez | Spain |

| | | |
|---|------------------|----------|
| P 12-13 - The IEO lab transition from HC2 to Cobas in HPV detection: sensitivity and specificity for CIN2+ in 10213 consecutive samples | M.T.Sandri | Italy |
| P 12-14A- Comparison between liquid based cytology and human papillomavirus detection as tests for cervical cancer screening | D. Rieder | Austria |
| P 12-14B- The correlation between the molecular biological detection of human papillomavirus and the grade of cervical neoplasia | D. Rieder | Austria |
| P 12-15A- The importance of women's age in the screening programs for the timely discovery of cervical cancer and its precursors | A. Trauner | Austria |
| P 12-15B- An analysis of risk assessment at the genesis of cervix carcinoma | A. Trauner | Austria |
| P 12-16 - Pilot feasibility study on use of the Xpert HPV assay with Colli-Pee collected, UCM preserved urine | V. Vankerckhoven | Belgium |
| P 12-17 - Evaluation of the Roche Cobas®HPV assay with Colli-Pee™ collected, UCM preserved urine | A. Vorsters | Belgium |
| P 12-18 - HPV-related lesions in anal and cervix pap-smears in HIV+ patients under anti-retroviral treatment. Interest of cytology coupled to rapid HPV PCR | F. Walker | France |
| P 12-19 - Detection of high-risk HPV genotypes among the Ecuadorian female population: study of 1643 cases with Roche Cobas 4800 HPV | H. Zambrano | Ecuador |
| P 12-20 - Sociodemographic, practical and attitudinal barriers to cervical cancer screening in underscreened and never screened Japanese women. | S. Hanley | Japan |
| P 12-21 - Compatibility of Genefirst Papilloplex™ HR-HPV genotyping assay for testing first void urine specimens | D. Kapadia | Belgium |
| P 12-22 - Non-invasive first-void urine sampling and acceptability to monitor the impact of vaccination against HPV | S. Van Keer | Belgium |
| P 12-23 - Detection of high grade CIN using DNA testing with partial genotyping for HPV 16/18 | S. Kikawa | Japan |
| P 12-24 - HPV testing for cervical cancer screening: experience in Centro Medicina Laboratorial Germano de Sousa/ Hospital CUF Descobertas | M. Sousa | Portugal |
| P 12-25- XPERT HPV assay as a promising test in clinical setting: analytic and diagnostic performances | S. Rosini | Italy |

P 13 Immunology

| | | |
|--|-----------|-------|
| P 13-1 - Comparative study of the immunomodulatory properties of different coriolus versicolor-based formulations administered orally or topically in the vagina in healthy mice | D. Dexeus | Spain |
|--|-----------|-------|

P 14 Low resource settings

| | | |
|---|---------------|-------|
| P 14-1 - Precancerous and cancerous lesions of the uterine cervix in Kinshasa: association with HPV infection | C. Ali-Risasi | Congo |
|---|---------------|-------|

P 15 Molecular markers

| | | |
|--|-------------------|----------|
| P 15-1 - Investigation of membrane proteins offers significant insights on the process of cervical cancerogenesis | P. Christou | Greece |
| P 15-2 - New screening protocol with dual-stained cytology triage | M.D.Comes | Spain |
| P 15-3 - Performance of the ONCOEE test for high-grade cervical disease and cancer detection among Honduran women | A. Ferrera | Honduras |
| P 15-4 - Systems biology study focusing on the secretome of cervical cell lines reveals matrix remodeling and oxidative stress response as pivotal pathways implicated in carcinogenesis | G. Kontostathi | Greece |
| P 15-5 - Expression of p16/Ki67 dual-staining depending on most common HPV genotypes in cervical lesions | I. Krivak Bolanca | Croatia |

P 16 New technologies

| | | | |
|---------|---|-------------|---------|
| P 16-1 | - Detection and quantification of HPV-mRNA in sentinel lymph nodes of cervical cancer patients by digital PCR and real-time PCR - A comparison of methods | K. Carow | Germany |
| P 16-2 | - Validation of a new method for high-risk HPV detection with the XPERT® HPV assay in in PAP-SPIN™ medium | C. Cuvelier | Belgium |
| P 16-3A | - Application of robotic single-site surgery for benign ovarian tumor | S.H. Kwon | Korea |
| P 16-3B | - Robotic single-site surgery in carcinoma in situ of cervix: a pilot study | S.H. Kwon | Korea |

P 17 Screening methods

| | | | |
|---------|--|----------------|----------|
| P 17-1 | - Study protocol of the choice trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program | B. Andersen | Denmark |
| P 17-2 | - Concordance between self-sampling and professionally taken cervical HPV test - Result from a population based cohort study | L. Bergengren | Sweden |
| P 17-3 | - Screening of cervical cancer in Senegal: a strategy of innovative health center Nabil Choucair | O. Gassama | Senegal |
| P 17-4 | - HPV-positivity rate in randomised HPV self-sampling study among Slovenian non-responders: comparison of the results between three self-sampling devices | N. Nolde | Slovenia |
| P 17-5 | - Anal cancer screening: characteristics of participants who used two hands for a self-anal examination (SAE) | A. Nyitray | USA |
| P 17-6 | - Self-sampling in CIN2+ detection: sensitivity and specificity of different RLU cut-off in specimens from 786 women | M.T. Sandri | Italy |
| P 17-7 | - Preliminary evaluation of cervical cancer screening by cytology and HPV testing in north-western region of Romania | O. Suteu | Romania |
| P 17-8 | - Is there evidence for cervical cancer screening in elderly women? | L.H. Thamsborg | Denmark |
| P 17-9 | - Current standards and options for national cervical cancer screening programme in Croatia | J. Zekan | Croatia |
| P 17-10 | - Clinical value of fully automated Ki67/p16 dual staining as biomarkers for triage of HPV positive women in a screening program | I. Øvestad | Norway |
| P 17-11 | - The effect of anal cancer awareness and anxiety on screening in men who have sex with men | A. Nyitray | USA |
| P 17-12 | - Focalpoint computer-assisted PAP test screening: validation technology study for implementation in a public health service | T.R. Martins | Brazil |

P 18 Sexually transmitted diseases and HPV infection

| | | | |
|--------|--|--------------|--------|
| P 18-1 | - The vaginal microbiota of women with threatened pregnancy who subsequently have ongoing pregnancy versus those who subsequently have miscarriage in the first trimester of gestation | A. Akhmedova | Russia |
| P 18-2 | - The prevalence of human papillomavirus infection and other sexually transmitted infections in the anus of Japanese men who have sex with men: a molecular and cytological analysis | H. Iwamoto | Japan |

P 19 Vulvar diseases and neoplasia

| | | | |
|--------|---|---------------------|---------|
| P 19-1 | - Giant condyloma accuminatum mimicking vulvar verrucous carcinoma | F. Ghaemmaghaminori | Iran |
| P 19-2 | - Advanced vulvar cancer. Two different cases of the same disease | A.M. Serrano | Spain |
| P 19-3 | - Immune activation enhances epithelial nerve growth in localized provoked vulvodynia | P. Tammola | Finland |

P 20 HPV therapeutic vaccines

| | | | |
|--------|---|---------|-------------|
| P 20-1 | - Therapeutic HPV16/18 adenovirus-vector-base vaccine proof of concept in mice and non human primates | S. Khan | Netherlands |
|--------|---|---------|-------------|